Sanofi (SAN.PA) analysis

Loading the Vaultflake…

Health is the debt of two books, medicine and vaccine, not of a patent that lasts forever. Quality separates the Dupixent margin from the vaccine, without treating the Regeneron share as measured. Growth follows covered treatments, not a year of heavy flu. P/E is read against a year of many sales, not against that peak. Shareholder return is the dividend, checked against cash. Do not read it as the vaccine that repeats on its own.

The P/E of a year of many sales is not the earnings if the payer cuts back. EV/EBITDA is read without treating flu as the pace of Dupixent. Do not use Regeneron's multiple as if the shared sale were already divided inside one set of accounts. A dash if the SAN.PA cache is cold.

Limits of this report

Not advice on Sanofi. Vaultflake does not state the Dupixent share, does not describe the medicine or how it is given, and does not state the patent date. Read the filings. A past dividend is not a right. The table is a snapshot, not a target price.

Questions from this report